Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Clinical Study to Evaluate the Safety and Efficacy of NK Cells (Combined With Standard Therapy) in the Treatment of Solid Tumor Patients

NCT06284226 is registered in ClinicalTrials.gov with Beijing Kejing Biotechnology Co., Ltd. as lead sponsor.

NCT NCT06284226
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06284226 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Clinical Study to Evaluate the Safety and Efficacy of NK Cells (Combined With Standard Therapy) in the Treatment of Solid Tumor Patients
Lead sponsor
Beijing Kejing Biotechnology Co., Ltd.
Phase
Phase 1
Overall status
Withdrawn
Start date
March 25, 2022
Completion date
December 31, 2025
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumors (pancreatic cancer, esophageal cancer, gastric cancer, cholangiocarcinoma, lung cancer and ovarian cancer)